>
Switch to:

Intec Parent EBITDA per Share

: $-12.97 (TTM As of Mar. 2021)
View and export this data going back to 1996. Start your Free Trial

Intec Parent's EBITDA per Share for the three months ended in Mar. 2021 was $-3.31. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2021 was $-12.97.

During the past 3 years, the average EBITDA per Share Growth Rate was 51.70% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 21.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Intec Parent's EBITDA per Share or its related term are showing as below:

NAS:NTEC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -15.5   Med: -1.6   Max: 51.7
Current: 51.7

-15.5
51.7

During the past 8 years, the highest 3-Year average EBITDA per Share Growth Rate of Intec Parent was 51.70% per year. The lowest was -15.50% per year. And the median was -1.60% per year.

NAS:NTEC's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 192 Companies
in the Biotechnology industry.

( Industry Median: -3.90 vs. NAS:NTEC: 51.70 )

Intec Parent's EBITDA for the three months ended in Mar. 2021 was $-3.65 Mil.

During the past 3 years, the average EBITDA Growth Rate was 23.90% per year. During the past 5 years, the average EBITDA Growth Rate was -19.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 8 years, the highest 3-Year average EBITDA Growth Rate of Intec Parent was 23.90% per year. The lowest was -83.60% per year. And the median was -40.60% per year.


Intec Parent EBITDA per Share Historical Data

The historical data trend for Intec Parent's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intec Parent Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EBITDA per Share
Premium Member Only Premium Member Only Premium Member Only -91.92 -129.46 -108.90 -77.23 -14.60

Intec Parent Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
EBITDA per Share Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.85 -3.31 -3.38 -2.97 -3.31

Intec Parent EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Intec Parent's EBITDA per Share for the fiscal year that ended in Dec. 2020 is calculated as

EBITDA per Share(A: Dec. 2020 )
=EBITDA/Shares Outstanding (Diluted Average)
=-12.626/0.865
=-14.60

Intec Parent's EBITDA per Share for the quarter that ended in Mar. 2021 is calculated as

EBITDA per Share(Q: Mar. 2021 )
=EBITDA/Shares Outstanding (Diluted Average)
=-3.652/1.105
=-3.30

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intec Parent  (NAS:NTEC) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Intec Parent EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Intec Parent's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Intec Parent Business Description

Intec Parent logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
N/A
Address
12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512
Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.
Executives
Linscott Walt Addison officer: Chief Business Officer 1860 MONTREAL ROAD TUCKER GA 30084
Sassi Nir officer: Chief Financial Officer 3 ELUL STREET, APT. 6 MODIIN L3 7176397
Navon Nadav officer: Chief Operating Officer 18 LEA IMENU STREET MODIIN L3 7177945
Maddaluna Anthony J director PFIZER INC. ATTN CORPORATE SECRETARY 235 RAST 42ND STREET NEW YORK NY 10017
Hayes William B director 231 MAPLE AVENUE BURLINGTON NC 27215
Pomerantz Roger director 711 HARVEST HILL ROAD CHALFONT PA 18914
Karah Hila director 9 HALAMISH STREET CAESAREA INDUSTRIAL PARK CAESAREA L3 38900
Kozarich John W director 10275 SCIENCE CENTER DR SAN DIEGO CA 92121
Meckler Jeffrey A director, officer: Chief Executive Officer 740 BROADWAY 9TH FLOOR NEW YORK NY 10003
Gendreau R Michael officer: Chief Medical Officer 4350 EXECUTIVE DRIVE SUITE 325 SAN DIEGO CA 92121
Oren Dan 10 percent owner 1 DEXCEL STREET OR AKIVA L3 30600000
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET OR AKIVA L3 3060000
Bianco Gil director 7 HAORANIM STREET BAZRA L3 60944
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)